The Lubrizol Corporation has announced the reorganization of its Personal, Home and Health Care business lines, integrating them under a newly dedicated brand, Lubrizol Life Science.
The change reflects the company’s commitment to evolve with the beauty, health, home and wellness markets, which continue to cross over and converge. The newly formed Lubrizol Life Science team seeks to enhance the value of its solutions and services to customers and end users through its collective expertise in chemistry, applications and market insights.
“Lubrizol Life Science brings together a great variety of formulation and product development experience to sit under one umbrella,” says Lubrizol Advanced Materials President Rick Tolin. “Our internal capabilities are focused and aligned to help our customers quickly meet the expectations of today’s consumers for products that ensure them of a healthier, more beautiful and comfortable life.”
The newly aligned Lubrizol Life Science team is placing a priority on developing and testing products in partnership with customers, engineering breakthroughs and co-driving initiatives that fuel growth. Practices and processes emphasize agile innovation, enabling the organization to act at the speed of a start-up, while responding with the reach, resources and delivery of a global leader. The new brand will also emphasize the proactive innovation needed to bring market-ready solutions to customers, while capitalizing on the reliability of Lubrizol’s 90 years of science and efficacy.
Tolin points out, “Our beauty, health and home customers can count on us bringing truly differentiated products to market, formulated with ingredients that are consumer-driven and backed by the reliability of Lubrizol.” Tolin adds, “The Lubrizol Life Science team is poised to service customers throughout the value chain, from concept to commercialization. Once viewed by customers as a chemical and ingredient supplier, we have evolved into an essential, concept-to-commercialization solutions partner.”
Lubrizol Life Science also plans to add strategic technology, capability and talent by investing to expand its portfolio, including new acquisitions that bring unique opportunities and synergies.
© 2019 David Mazor
Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.